Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Radar Therapeutics
Berkeley, California, United Statesradartx.bio ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Radar Therapeutics has demonstrated proof-of-concept for its programmable mRNA therapies in preclinical settings. Their technology enables cell-specific expression of therapeutic payloads by sensing endogenous RNA markers, aiming to avoid off-target effects and improve safety. No human clinical results have been reported yet
- Therapeutic areas
- Other
- Modalities
- mRNA-based therapeuticsprogrammable genetic medicines
- Industry
- Biotech
02
Partnerships
No major pharmaceutical partnerships disclosed as of May 2024. The company has received industry recognition/awards from AbbVie, J&J West Coast Cell & Gene Therapy Symposium, and Amgen Diversity Initiative
Beyond the preview
Go deeper on Radar Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Radar Therapeutics.